View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPierrel 過去の業績過去 基準チェック /46Pierrelは、平均年間7.3%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.4% 4.4%収益成長率で 成長しています。 Pierrelの自己資本利益率は12.1%であり、純利益率は11.5%です。主要情報7.33%収益成長率-16.96%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率4.36%株主資本利益率12.06%ネット・マージン11.53%前回の決算情報30 Jun 2023最近の業績更新Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.80, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 35% over the past three years.New Risk • Oct 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (91% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€87.9m market cap, or US$93.1m).New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€87.3m market cap, or US$93.0m).New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€86.0m market cap, or US$92.0m).New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€85.4m market cap, or US$93.9m).お知らせ • Aug 02Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million.Pierrel S.p.A. (BIT:PRL) entered into agreements to acquire assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million on May 2, 2023. The purchase consideration payable in cash, is subject to closing and other adjustments. These local anesthetic products had annual sales in 2022 of approximately $30 million. The transaction, which is subject to information or consultation requirements with relevant works councils and other closing conditions, is expected to be completed in the third quarter of 2023. The impact of ongoing operations were not material to 3M's financial results.Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million. on August 1, 2023.Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.22, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 12% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).Is New 90 Day High Low • Feb 26New 90-day high: €0.23The company is up 56% from its price of €0.15 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Feb 17New 90-day high: €0.22The company is up 51% from its price of €0.14 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Reported Earnings • Nov 16Third quarter 2020 earnings released: €0.003 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €2.54m (down 54% from 3Q 2019). Net loss: €634.0k (down 489% from profit in 3Q 2019).お知らせ • Sep 22Gianluca Vacchi acquired 2% stake in Pierrel SpA.Gianluca Vacchi acquired 2% stake in Pierrel SpA on January 10, 2007. Gianluca Vacchi completed the acquisition of 2% stake in Pierrel SpA on January 10, 2007.Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €3.76m, up 252% from the prior year. Total revenue was €22.7m over the last 12 months, up 7.8% from the prior year.収支内訳Pierrel の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:2FJ0 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 232737031 Mar 232517031 Dec 222417030 Sep 222517030 Jun 222427031 Mar 222337031 Dec 212437030 Sep 212136030 Jun 211916031 Mar 212136031 Dec 201826030 Sep 202036030 Jun 202346031 Mar 202126031 Dec 192226030 Sep 192216030 Jun 192116031 Mar 192116031 Dec 182016030 Sep 182126030 Jun 182026031 Mar 181905031 Dec 1717-35030 Sep 1715-85030 Jun 1714-95031 Mar 1714-85031 Dec 1615-65030 Sep 1614-26030 Jun 1614-16031 Mar 161506031 Dec 151606030 Sep 15510-2030 Jun 15860031 Mar 151303031 Dec 1415-26030 Sep 1430-1617030 Jun 1429-1617031 Mar 1429-1217031 Dec 1330-1317030 Sep 1330-1418030 Jun 1336-1218031 Mar 1340-13190質の高い収益: 2FJ0には€741.2K } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が30th June, 2023に影響を及ぼしています。利益率の向上: 2FJ0の現在の純利益率 (11.5%)は、昨年(7.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 2FJ0過去 5 年間で収益を上げており、収益は年間7.3%増加しています。成長の加速: 2FJ0の過去 1 年間の収益成長率 ( 75.3% ) は、5 年間の平均 ( 年間7.3%を上回っています。収益対業界: 2FJ0の過去 1 年間の収益成長率 ( 75.3% ) はPharmaceuticals業界15.1%を上回りました。株主資本利益率高いROE: 2FJ0の 自己資本利益率 ( 12.1% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/28 07:13終値2024/01/26 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pierrel S.p.A. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Luigi TardellaEnVent Capital Markets LimitedFabrizio BariniIntermonte SIM S.p.A.
Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.
Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.
Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).
Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.80, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 35% over the past three years.
New Risk • Oct 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (91% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€87.9m market cap, or US$93.1m).
New Risk • Sep 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€87.3m market cap, or US$93.0m).
New Risk • Sep 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€86.0m market cap, or US$92.0m).
New Risk • Aug 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks High level of debt (81% net debt to equity). Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (€85.4m market cap, or US$93.9m).
お知らせ • Aug 02Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million.Pierrel S.p.A. (BIT:PRL) entered into agreements to acquire assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million on May 2, 2023. The purchase consideration payable in cash, is subject to closing and other adjustments. These local anesthetic products had annual sales in 2022 of approximately $30 million. The transaction, which is subject to information or consultation requirements with relevant works councils and other closing conditions, is expected to be completed in the third quarter of 2023. The impact of ongoing operations were not material to 3M's financial results.Pierrel S.p.A. (BIT:PRL) completed the acquisition of assets associated with Dental local anesthetic business from 3M Company (NYSE:MMM) for $70 million. on August 1, 2023.
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.22, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 12% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 07Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €4.83m (up 12% from 2Q 2021). Net loss: €1.00m (loss widened 329% from 2Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 5.4% growth forecast for the industry in Germany.
Reported Earnings • Jun 11First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: €5.99m (down 8.1% from 1Q 2021). Net income: €542.0k (down 42% from 1Q 2021). Profit margin: 9.1% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.0% growth forecast for the industry in Germany.
Reported Earnings • May 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €23.8m (up 30% from FY 2020). Net income: €2.94m (up 55% from FY 2020). Profit margin: 12% (up from 10% in FY 2020). The increase in margin was driven by higher revenue.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 18Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €4.96m (up 96% from 3Q 2020). Net income: €673.0k (up €1.31m from 3Q 2020). Profit margin: 14% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 30First quarter 2021 earnings released: EPS €0.004 (vs €0.003 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: €6.52m (up 27% from 1Q 2020). Net income: €940.0k (up 34% from 1Q 2020). Profit margin: 14% (in line with 1Q 2020).
Reported Earnings • Mar 13Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €18.3m (down 17% from FY 2019). Net income: €1.90m (down 15% from FY 2019). Profit margin: 10% (in line with FY 2019).
Is New 90 Day High Low • Feb 26New 90-day high: €0.23The company is up 56% from its price of €0.15 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Feb 17New 90-day high: €0.22The company is up 51% from its price of €0.14 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Reported Earnings • Nov 16Third quarter 2020 earnings released: €0.003 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: €2.54m (down 54% from 3Q 2019). Net loss: €634.0k (down 489% from profit in 3Q 2019).
お知らせ • Sep 22Gianluca Vacchi acquired 2% stake in Pierrel SpA.Gianluca Vacchi acquired 2% stake in Pierrel SpA on January 10, 2007. Gianluca Vacchi completed the acquisition of 2% stake in Pierrel SpA on January 10, 2007.
Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €3.76m, up 252% from the prior year. Total revenue was €22.7m over the last 12 months, up 7.8% from the prior year.